XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.24.3

GOODWILL AND OTHER INTANGIBLE ASSETS | 9 Months Ended
--- | ---
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions |  |  |
Balance at December 31, 2023 | $ | 21,169 |  |  |
Acquisitions (Note 4) | 580 |  |  |
Currency translation and other adjustments | 2 |  |  |
Balance at September 30, 2024 | $ | 21,751 |  |  |
Other Intangible Assets Other intangible assets consisted of the following:
| Estimated Useful Lives |  | September 30, 2024 |  | December 31, 2023
Dollars in millions |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net
R&D technology(a) | 6 years |  | $ | 1,980 |  |  | $ | (193) |  |  | $ | 1,787 |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Acquired marketed product rights(a) | 3 – 15 years |  | 63,435 |  |  | (47,048) |  |  | 16,387 |  |  | 63,076 |  |  | (40,184) |  |  | 22,892 |
Capitalized software | 3 – 10 years |  | 1,529 |  |  | (1,114) |  |  | 415 |  |  | 1,497 |  |  | (1,027) |  |  | 470 |
IPRD(a) |  |  | 8,375 |  |  | — |  |  | 8,375 |  |  | 3,710 |  |  | — |  |  | 3,710 |
Total |  |  | $ | 75,319 |  |  | $ | (48,355) |  |  | $ | 26,964 |  |  | $ | 68,283 |  |  | $ | (41,211) |  |  | $ | 27,072 |
(a) Includes assets acquired in connection with Mirati and RayzeBio acquisitions, as further described in "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements." Amortization expense of Other intangible assets was $2.4 billion and $7.3 billion during the three and nine months ended September 30, 2024 and $2.3 billion and $6.9 billion during the three and nine months ended September 30, 2023, respectively. The other intangible assets impairments were as follows (dollars in millions):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Cost of goods sold | $ | — |  |  | $ | 60 |  |  | $ | 280 |  | (a) | $ | 80 |
Research and development | — |  |  | — |  |  | 590 |  | (b) | — |
Other income/(expense) | 47 |  |  | 29 |  |  | 47 |  |  | 29 |
Total | $ | 47 |  |  | $ | 89 |  |  | $ | 917 |  |  | $ | 109 |
(a) Impairment relates to Inrebic, which resulted from lower revised cash flow projections. The charge represented a partial impairment based on the asset's carrying value over its estimated fair value using discounted cash flow projections. (b) Impairment relates to alnuctamab, which resulted from portfolio prioritization. The charge represented a full write-down of the asset.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration